Kyle T. Baron, Pharm.D., Ph.D.

Principal Scientist I

Kyle joined Metrum in 2010 after receiving his Pharm.D. and Ph.D. in  Experimental and Clinical Pharmacology from the University of Minnesota. As a member of our translational and systems pharmacology group, Kyle has worked to support sponsor development programs in a variety of therapeutic areas, including chronic hepatitis C infection, HIV, calcium homeostasis and bone health, type-2 diabetes, and cystic fibrosis.  

Kyle is the developer and maintainer of mrgsolve (https://mrgsolve.github.io) and also leads workshops at all levels to guide other M&S scientists in the effective use of this simulation tool in PKPD, PBPK, and QSP modeling. Kyle also serves as adjunct faculty in Experimental and Clinical Pharmacology at the University of Minnesota.  

Recent publications by this scientist

A physiologically-based pharmacokinetic model for Voriconazole explores differences in pharmacokinetics between adults and children

October 8, 2018

Elmokadem A. Poster presented at 2018 American Conference on Pharmacometrics (ACoP9). San Diego, CA. 9 Oct 2018. Abstract #M-003.

Download PDF

Population pharmacokinetics and exposure-response (efficacy and safety/tolerability) of empagliflozin in patients with type 2 diabetes

September 1, 2016

Baron KT, Macha S, Broedl UC, Nock V, Retlich S, Riggs M.  Diabetes Ther. 2016 Sep;7(3):455-71.

Download PDF